Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 19/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10718871 | 0.81 | CSNK2A1 (0.36) | KMOKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL27956903 | 0.81 | KMO (0.36) | KMOKDM4EALDH1A1SMN1; SMN2 | |
| Lithium Ion SCHEMBL31704998 | 0.79 | CA1 (0.34) | KMOKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL31589970 | 0.76 | P2RX7 (0.57) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2659157 | 0.76 | ALDH1A1 (0.35) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2762628 | 0.76 | KDM4E (0.40) | KDM4EALDH1A1 | |
| SCHEMBL31126262 | 0.76 | KDM4E (0.55) | KMOKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL163539 | 0.76 | KMO (0.50) | KMO | |
| SCHEMBL87765 | 0.76 | KDM4E (0.55) | KMOKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL163540 | 0.76 | KMO (0.50) | KMOKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114702506-A | 11-carbonyl-20-ethoxy economic oridonin and 14-OH esterified series derivatives and application thereof | 郑州大学 | 2022-07-05 | — | — | CN | claimed |
| WO-2022078279-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 昆山新蕴达生物科技有限公司 | 2022-04-21 | — | — | WO | claimed |
| WO-2025215110-A1 | NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-10693086-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-06-23 | — | — | US | disclosed |
| US-20180366660-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-12-20 | — | — | US | disclosed |
| US-9447078-B2 | Substituted heterocyclic compounds for disease treatment | ACUCELA INC. (US) | 2016-09-20 | — | — | US | disclosed |
| CN-103360407-B | A kind of Thienopyrimidine analog derivative, its preparation method and in application pharmaceutically | 上海希迈医药科技有限公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-102757420-B | Heterotactic aryl carboxylic acid compound, preparation method thereof, medicine composition comprising compound and application of compound | SHANGHAI INST MATERIA MEDICA | 2015-02-04 | — | — | CN | disclosed |
| EP-2804605-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013109991-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-07-25 | — | — | WO | disclosed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| EP-2406253-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | Pfizer Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103437-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2009097014-A2 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | KMO 470/4885KDM4E 3346/4885ALDH1A1 1316/4885 |
| US-10693086-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | ORC3, LEF1, OCIAD1 | KMO 1124/4885KDM4E 2493/4885ALDH1A1 147/4885 |
| US-20180366660-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | ORC3, LEF1, OCIAD1 | KMO 1124/4885KDM4E 2493/4885ALDH1A1 147/4885 |
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | CLN6, ALDH1A2, PDE6D | KMO 984/4885KDM4E 3182/4885ALDH1A1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.